Emi Nomura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emi Nomura has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Nozomi Hishikawa
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
17 shared publications- Toru Yamashita
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
17 shared publications Mami Takemoto
Department of Neurology Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Okayama Japan
16 shared publications- Koh Tadokoro
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
10 shared publications - Kota Sato
Department of Neurology Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
10 shared publications Ryuta Morihara
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
10 shared publications
Latest Publications
- 3 November 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Catatonia Developed After Intrathecal Baclofen Dose Adjustment
Catatonia is a neuropsychiatric disorder characterized by motor, affective, and cognitive‐behavioral signs. Baclofen is a γ‐aminobutyric acid analog that produces muscle relaxation and is used for various conditions associated with spasticity. Complications associated with baclofen use include life‐threatening withdrawal and intoxication symptoms. Catatonia associated with baclofen administration has rarely been reported. Here, we report a case of catatonia associated with baclofen dose adjustment in a 54‐year‐old woman receiving intrathecal baclofen therapy for spastic paraplegia. Her symptoms responded to the diazepam challenge test and subsequently improved with lorazepam treatment. Clinicians should pay attention to the adjustment period and dose of baclofen and keep in mind the possibility of developing psychiatric symptoms, including catatonia.
- 3 November 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Catatonia Developed After Intrathecal Baclofen Dose Adjustment
Catatonia is a neuropsychiatric disorder characterized by motor, affective, and cognitive‐behavioral signs. Baclofen is a γ‐aminobutyric acid analog that produces muscle relaxation and is used for various conditions associated with spasticity. Complications associated with baclofen use include life‐threatening withdrawal and intoxication symptoms. Catatonia associated with baclofen administration has rarely been reported. Here, we report a case of catatonia associated with baclofen dose adjustment in a 54‐year‐old woman receiving intrathecal baclofen therapy for spastic paraplegia. Her symptoms responded to the diazepam challenge test and subsequently improved with lorazepam treatment. Clinicians should pay attention to the adjustment period and dose of baclofen and keep in mind the possibility of developing psychiatric symptoms, including catatonia.
- 24 September 2026
- Published by Wiley in Clinical Genetics
Loss‐Of‐Function CCM Gene Variants in Japanese Patients With Cerebral Cavernous Malformations
Hereditary cerebral cavernous malformations (CCMs) are characterized by lesion multiplicity and the formation of de novo lesions, in contrast to sporadic forms. We performed sequencing analyses covering the known autosomal dominant loci CCM1/ KRIT1 , CCM2/ CCM2 ( Malcavernin ), and CCM3/ PDCD10 in 11 patients from eight families with CCMs. All patients had multiple lesions, and de novo lesions were observed in four patients (36.4%). Heterozygous loss‐of‐function variants were identified in seven families, including four variants of KRIT1 , two of CCM2 , and one of PDCD10 . Among them, c.1730 + 4_1730 + 7delAGTA in KRIT1 and c.609G>A (p.Lys203=) in CCM2 were putative splicing variants located outside the invariant GT/AG dinucleotides at the splice junction because AI‐based prediction tools indicated that both variants may disrupt normal splicing. In vitro splicing assays confirmed that the AI‐based predictions were correct, and the same aberrant splicing pattern was reproduced by reverse transcription PCR using tissue‐derived RNA for the c.609G>A variant in CCM2 . In one patient with numerous CCM lesions, whole‐genome sequencing was performed, which showed no abnormalities in the three known CCM loci, including deep intronic and structural variants. This may indicate the technological limitations of current bioinformatics analyses or the presence of a novel CCM gene.
- 24 September 2026
- Published by Wiley in Clinical Genetics
Loss‐Of‐Function CCM Gene Variants in Japanese Patients With Cerebral Cavernous Malformations
Hereditary cerebral cavernous malformations (CCMs) are characterized by lesion multiplicity and the formation of de novo lesions, in contrast to sporadic forms. We performed sequencing analyses covering the known autosomal dominant loci CCM1/ KRIT1 , CCM2/ CCM2 ( Malcavernin ), and CCM3/ PDCD10 in 11 patients from eight families with CCMs. All patients had multiple lesions, and de novo lesions were observed in four patients (36.4%). Heterozygous loss‐of‐function variants were identified in seven families, including four variants of KRIT1 , two of CCM2 , and one of PDCD10 . Among them, c.1730 + 4_1730 + 7delAGTA in KRIT1 and c.609G>A (p.Lys203=) in CCM2 were putative splicing variants located outside the invariant GT/AG dinucleotides at the splice junction because AI‐based prediction tools indicated that both variants may disrupt normal splicing. In vitro splicing assays confirmed that the AI‐based predictions were correct, and the same aberrant splicing pattern was reproduced by reverse transcription PCR using tissue‐derived RNA for the c.609G>A variant in CCM2 . In one patient with numerous CCM lesions, whole‐genome sequencing was performed, which showed no abnormalities in the three known CCM loci, including deep intronic and structural variants. This may indicate the technological limitations of current bioinformatics analyses or the presence of a novel CCM gene.
- 17 October 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 11 (1) , 58-60
Novel ABCD1 mutation detected in a symptomatic female carrier of adrenoleukodystrophy
We report a case of a symptomatic female carrier of X‐linked adrenoleukodystrophy (ALD) with a novel ABCD1 gene mutation. She has developed slowly progressive gait disturbance since age 40, and her father and sister had similar symptoms. When admitted to our hospital at age 66, blood analysis showed slight increase of very long‐chain fatty acids (VLCFA), and DNA analysis of ABCD1 gene revealed a novel heterozygous missense mutation (c.1700 A>C, p.Gln567Pro). The genetic testing for ABCD1 gene can be considered in female patients over middle age presenting spastic gait, because female ALD carriers tend to be symptomatic beyond age 60.
- 17 October 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 11 (1) , 58-60
Novel ABCD1 mutation detected in a symptomatic female carrier of adrenoleukodystrophy
We report a case of a symptomatic female carrier of X‐linked adrenoleukodystrophy (ALD) with a novel ABCD1 gene mutation. She has developed slowly progressive gait disturbance since age 40, and her father and sister had similar symptoms. When admitted to our hospital at age 66, blood analysis showed slight increase of very long‐chain fatty acids (VLCFA), and DNA analysis of ABCD1 gene revealed a novel heterozygous missense mutation (c.1700 A>C, p.Gln567Pro). The genetic testing for ABCD1 gene can be considered in female patients over middle age presenting spastic gait, because female ALD carriers tend to be symptomatic beyond age 60.
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- 29 June 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 255-258
A Japanese case of successful surgical resection of cerebral cavernous malformations with a CCM2 mutation
- 29 June 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 255-258
A Japanese case of successful surgical resection of cerebral cavernous malformations with a CCM2 mutation
- 1 March 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (2) , 98-101
A case of a heterozygous ABCC6 mutation showing recurrent ischemic strokes and intracranial hemorrhages
- 1 March 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (2) , 98-101
A case of a heterozygous ABCC6 mutation showing recurrent ischemic strokes and intracranial hemorrhages
- 1 November 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (1) , 30-34
Three cases of GFAP astrocytopathy, one with bilateral ovarian teratoma
- 1 November 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (1) , 30-34
Three cases of GFAP astrocytopathy, one with bilateral ovarian teratoma
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 474-477
Successful treatment of anti‐GAD antibody‐associated autoimmune cerebellar ataxia with combined immunotherapies
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 474-477
Successful treatment of anti‐GAD antibody‐associated autoimmune cerebellar ataxia with combined immunotherapies
- Open Access
- 14 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Author Correction: Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 14 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Open AccessAuthor Correction: Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis
An amendment to this paper has been published and can be accessed via a link at the top of the paper.